EMA has published an overview of its key recommendations of 2022 regarding the authorisation and safety monitoring of veterinary medicines. (...)
In 2022, EMA recommended 89 medicines for marketing authorisation.
Of these, 411 had a new active substance which had never been authorised in the European Union (EU) before. The overview of the 2022 key recommendations published today includes figures on the authorisation of medicines and a selection of new treatments that represent significant progress in their therapeutic areas. (...)
Post
Nessun commento:
Posta un commento